Last close As at 05/08/2026
GBP17.92
▲ 6.00 (0.34%)
Market capitalisation
GBP501m
Research: TMT
With the acquisition of Glassman High Voltage, XP continues in its quest to expand its product portfolio to include high-voltage and high-power products. The acquisition should help XP to further penetrate key accounts, as well as adding new customers. XP is paying £31.8m in cash, funded by extending the company’s credit facility, and expects the deal to be earnings enhancing in FY18. We increase our FY18 and FY19 normalised EPS forecasts by 3.6% and 6.1% respectively. We forecast a net debt/EBITDA ratio of 0.8x at end FY18, well below the company’s 2.0x ceiling.
XP Power |
Rounding out the portfolio |
Acquisition |
Tech hardware & equipment |
10 May 2018 |
Share price performance
Business description
Next events
Analysts
XP Power is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||||||||||||||||
With the acquisition of Glassman High Voltage, XP continues in its quest to expand its product portfolio to include high-voltage and high-power products. The acquisition should help XP to further penetrate key accounts, as well as adding new customers. XP is paying £31.8m in cash, funded by extending the company’s credit facility, and expects the deal to be earnings enhancing in FY18. We increase our FY18 and FY19 normalised EPS forecasts by 3.6% and 6.1% respectively. We forecast a net debt/EBITDA ratio of 0.8x at end FY18, well below the company’s 2.0x ceiling.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/16 |
129.8 |
28.6 |
115.3 |
71.0 |
30.2 |
2.0 |
12/17 |
166.8 |
36.1 |
147.0 |
78.0 |
23.7 |
2.2 |
12/18e |
193.9 |
41.7 |
177.2 |
82.0 |
19.6 |
2.4 |
12/19e |
209.4 |
45.6 |
193.7 |
85.0 |
18.0 |
2.4 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Extending the product portfolio
XP Power has agreed to acquire Glassman High Voltage, a US-based designer and manufacturer of high-voltage, high-power conversion products. This extends XP’s product portfolio to include products that supply both high-power and high-voltage, complementing EMCO’s high-voltage, low-power products and Comdel’s RF power products. With limited sales capability of its own, Glassman products will be marketed by XP’s salesforce. While Glassman has some customers in common with XP, there is no overlap in terms of products sold to those customers, and it brings several new customers to the group.
Accretive in FY18
Glassman generated revenues of $17.3m and PBT of $2.9m in 2017 (16% margin). We have factored in pro-rated revenues at a growth rate of 10% in FY18, reflecting the exposure to the semiconductor manufacturing market, and 5% in FY19. This results in a revenue uplift of 4.3% in FY18e and 7.3% in FY19e, and an increase in our normalised EPS forecasts of 3.6% in FY18 and 6.1% in FY19. We forecast that the company will close FY18 with a net debt position of £38.3m.
Valuation: Reflects consistently profitable growth
On a P/E basis, XP is trading at a premium to global power converter companies and at a small discount to UK electronics companies, with a dividend yield at the top end of the range. XP generates EBITDA and EBIT margins at the top end of its peer group. We see scope for upgrades to earnings estimates from cross-selling and further market share gains in healthcare. The company is well funded to make further acquisitions, while maintaining its strong operating profitability.
Background to the deal
XP has agreed to pay $44.5m/£31.8m in cash to acquire the business and assets of Glassman High Voltage Inc (Glassman) – completion is expected by the end of May. Glassman was founded in 1977 by Sanford Glassman, the major shareholder, and is based in New Jersey, US. The company designs and supplies a range of standard, modified and custom high-voltage, high-power conversion products. Typically, its products are used in equipment involved in the ionisation and acceleration of particles – applications include semiconductor production equipment, vacuum/plasma processing, analytical instrumentation, medical diagnostic and test equipment. Glassman has a very comprehensive standard product portfolio and can also provide custom solutions. It has a manufacturing facility in New Jersey. The acquisition includes Glassman’s European sales operations, which are based in Hampshire, UK.
Sandy Glassman recently passed away; consequently Glassman is being acquired from his estate. On completion, the current President, Karolee Glassman, will leave and the general manager of the business, John Belden, will remain with the business and run Glassman within XP.
Financial profile
In 2017, Glassman generated revenues in the US of $17.3m/£12.4m and PBT of $2.9m/£2.0m (16.1% margin). This compares to a PBT margin of 21.6% for XP in FY17. The acquisition cost of $45m/£31.8m is on a debt- and cash-free basis. XP is extending its credit facility by $45m to fund the deal. This values the business on a trailing EV/Sales multiple of 2.6x compared to XP’s trailing multiple of 4.0x, and a trailing PBT multiple of 15.3x vs 18.7x for XP.
Changes to forecasts
We have revised our forecasts to reflect a revenue contribution of $11.1m in FY18 and $18.2m in FY19. We expect a reduction in the Glassman cost base due to the absence of founder-related expenses, which should bring EBITDA margins in line with the 25% group margin. We forecast that the net debt/EBITDA ratio will increase to 0.8x by the end of FY18, reducing to 0.5x by end FY19.
Exhibit 1: Changes to forecasts
£'m |
FY18e |
FY18e |
y-o-y |
FY19e |
FY19e |
y-o-y |
|||
Old |
New |
Change |
Old |
New |
Change |
||||
Revenues |
186.0 |
193.9 |
4.3% |
16.3% |
195.1 |
209.4 |
7.3% |
8.0% |
|
Gross profit |
86.0 |
89.8 |
4.4% |
15.7% |
90.2 |
97.1 |
7.6% |
8.1% |
|
Gross margin |
46.2% |
46.3% |
0.1% |
(0.2%) |
46.2% |
46.3% |
0.1% |
0.1% |
|
EBITDA |
46.6 |
48.5 |
4.3% |
16.4% |
49.5 |
53.1 |
7.2% |
9.4% |
|
EBITDA margin |
25.0% |
25.0% |
(0.0%) |
0.0% |
25.4% |
25.4% |
(0.0%) |
0.3% |
|
Normalised operating profit |
40.9 |
42.8 |
4.9% |
17.7% |
43.5 |
47.1 |
8.2% |
10.0% |
|
Normalised operating profit margin |
22.0% |
22.1% |
0.1% |
0.3% |
22.3% |
22.5% |
0.2% |
0.4% |
|
Reported operating profit |
39.5 |
41.4 |
5.0% |
27.5% |
42.3 |
45.9 |
8.4% |
10.8% |
|
Reported operating margin |
21.2% |
21.4% |
0.2% |
1.9% |
21.7% |
21.9% |
0.2% |
0.6% |
|
Normalised PBT |
40.3 |
41.7 |
3.5% |
15.4% |
42.9 |
45.6 |
6.1% |
9.3% |
|
Reported PBT |
38.9 |
40.3 |
3.7% |
25.1% |
41.7 |
44.4 |
6.2% |
10.1% |
|
Normalised net income |
33.2 |
34.4 |
3.6% |
20.6% |
35.4 |
37.6 |
6.1% |
9.3% |
|
Reported net income |
32.0 |
33.2 |
3.7% |
17.2% |
34.4 |
36.6 |
6.3% |
10.2% |
|
Normalised basic EPS (p) |
173.8 |
180.0 |
3.6% |
20.5% |
185.4 |
196.7 |
6.1% |
9.3% |
|
Normalised diluted EPS (p) |
171.1 |
177.2 |
3.6% |
20.5% |
182.5 |
193.7 |
6.1% |
9.3% |
|
Reported basic EPS (p) |
167.6 |
173.8 |
3.7% |
17.2% |
180.2 |
191.5 |
6.3% |
10.2% |
|
Dividend per share (p) |
82.0 |
82.0 |
0.0% |
5.1% |
85.0 |
85.0 |
0.0% |
3.7% |
|
Net debt/(cash) |
5.7 |
38.3 |
570.4% |
325.9% |
(6.2) |
25.8 |
(515.2%) |
(32.6%) |
Source: Edison Investment Research
Exhibit 2: Financial summary
£'m |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018e |
2019e |
||
31-December |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
INCOME STATEMENT |
||||||||||
Revenue |
|
|
93.9 |
101.1 |
101.1 |
109.7 |
129.8 |
166.8 |
193.9 |
209.4 |
Cost of Sales |
(49.0) |
(51.5) |
(51.0) |
(55.1) |
(67.8) |
(89.2) |
(104.2) |
(112.4) |
||
Gross Profit |
44.9 |
49.6 |
50.1 |
54.6 |
62.0 |
77.6 |
89.8 |
97.1 |
||
EBITDA |
|
|
23.3 |
26.0 |
27.6 |
29.7 |
33.0 |
41.7 |
48.5 |
53.1 |
Normalised operating profit |
|
|
21.0 |
23.3 |
24.5 |
25.9 |
28.8 |
36.4 |
42.8 |
47.1 |
Amortisation of acquired intangibles |
0.0 |
0.0 |
0.0 |
0.0 |
(0.4) |
(0.6) |
(1.4) |
(1.2) |
||
Exceptionals |
0.0 |
0.0 |
0.0 |
(0.3) |
(0.4) |
(3.3) |
0.0 |
0.0 |
||
Share-based payments |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Reported operating profit |
21.0 |
23.3 |
24.5 |
25.6 |
28.0 |
32.5 |
41.4 |
45.9 |
||
Net Interest |
(0.8) |
(0.4) |
(0.2) |
(0.2) |
(0.2) |
(0.3) |
(1.2) |
(1.6) |
||
Joint ventures & associates (post tax) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Exceptional & other financial |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Profit Before Tax (norm) |
|
|
20.2 |
22.9 |
24.3 |
25.7 |
28.6 |
36.1 |
41.7 |
45.6 |
Profit Before Tax (reported) |
|
|
20.2 |
22.9 |
24.3 |
25.4 |
27.8 |
32.2 |
40.3 |
44.4 |
Reported tax |
(4.5) |
(4.5) |
(4.8) |
(5.5) |
(6.3) |
(3.6) |
(6.8) |
(7.5) |
||
Profit After Tax (norm) |
15.7 |
18.4 |
19.5 |
20.2 |
22.3 |
28.8 |
34.6 |
37.8 |
||
Profit After Tax (reported) |
15.7 |
18.4 |
19.5 |
19.9 |
21.5 |
28.6 |
33.4 |
36.8 |
||
Minority interests |
(0.2) |
(0.2) |
(0.1) |
(0.2) |
(0.2) |
(0.3) |
(0.3) |
(0.3) |
||
Discontinued operations |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Net income (normalised) |
15.5 |
18.2 |
19.4 |
20.0 |
22.1 |
28.5 |
34.4 |
37.6 |
||
Net income (reported) |
15.5 |
18.2 |
19.4 |
19.7 |
21.3 |
28.3 |
33.2 |
36.6 |
||
Basic average number of shares outstanding (m) |
19 |
19 |
19 |
19 |
19 |
19 |
19 |
19 |
||
EPS - basic normalised (p) |
|
|
81.67 |
95.84 |
102.12 |
105.28 |
116.22 |
149.36 |
179.96 |
196.75 |
EPS - diluted normalised (p) |
|
|
81.35 |
95.05 |
101.07 |
104.32 |
115.33 |
147.00 |
177.18 |
193.70 |
EPS - basic reported (p) |
|
|
81.67 |
95.84 |
102.12 |
103.70 |
112.02 |
148.31 |
173.78 |
191.51 |
Dividend (p) |
50 |
55 |
61 |
66 |
71 |
78 |
82 |
85 |
||
Revenue growth (%) |
(9.4) |
7.7 |
0.0 |
8.5 |
18.3 |
28.5 |
16.3 |
8.0 |
||
Gross Margin (%) |
47.8 |
49.1 |
49.6 |
49.8 |
47.8 |
46.5 |
46.3 |
46.3 |
||
EBITDA Margin (%) |
24.8 |
25.7 |
27.3 |
27.0 |
25.4 |
25.0 |
25.0 |
25.4 |
||
Normalised Operating Margin |
22.4 |
23.0 |
24.2 |
23.6 |
22.2 |
21.8 |
22.1 |
22.5 |
||
BALANCE SHEET |
||||||||||
Fixed Assets |
|
|
52.8 |
53.3 |
56.1 |
65.4 |
73.2 |
88.1 |
128.3 |
132.3 |
Intangible Assets |
38.1 |
39.1 |
40.5 |
48.2 |
53.0 |
63.9 |
97.0 |
98.5 |
||
Tangible Assets |
13.2 |
12.7 |
14.4 |
16.1 |
19.1 |
22.5 |
29.6 |
32.1 |
||
Investments & other |
1.5 |
1.5 |
1.2 |
1.1 |
1.1 |
1.7 |
1.7 |
1.7 |
||
Current Assets |
|
|
39.3 |
42.2 |
47.0 |
53.5 |
65.7 |
83.5 |
96.6 |
110.0 |
Stocks |
19.8 |
20.4 |
25.2 |
28.7 |
32.2 |
37.8 |
45.7 |
49.3 |
||
Debtors |
14.2 |
15.4 |
16.0 |
17.5 |
21.5 |
23.8 |
29.2 |
31.6 |
||
Cash & cash equivalents |
4.1 |
5.0 |
3.8 |
4.9 |
9.2 |
15.0 |
17.7 |
25.2 |
||
Other |
1.2 |
1.4 |
2.0 |
2.4 |
2.8 |
6.9 |
4.0 |
4.0 |
||
Current Liabilities |
|
|
(20.2) |
(22.4) |
(18.6) |
(19.8) |
(25.8) |
(25.1) |
(28.4) |
(30.2) |
Creditors |
(11.1) |
(12.7) |
(14.4) |
(14.6) |
(16.1) |
(21.4) |
(24.7) |
(26.5) |
||
Tax and social security |
(1.6) |
(1.1) |
(1.7) |
(1.2) |
(3.3) |
(3.5) |
(3.5) |
(3.5) |
||
Short term borrowings |
(7.3) |
(8.5) |
(2.5) |
(4.0) |
(5.5) |
0.0 |
0.0 |
0.0 |
||
Other |
(0.2) |
(0.1) |
0.0 |
0.0 |
(0.9) |
(0.2) |
(0.2) |
(0.2) |
||
Long Term Liabilities |
|
|
(10.6) |
(3.7) |
(4.2) |
(10.0) |
(6.2) |
(29.6) |
(61.6) |
(56.6) |
Long term borrowings |
(7.4) |
0.0 |
0.0 |
(4.6) |
0.0 |
(24.0) |
(56.0) |
(51.0) |
||
Other long term liabilities |
(3.2) |
(3.7) |
(4.2) |
(5.4) |
(6.2) |
(5.6) |
(5.6) |
(5.6) |
||
Net Assets |
|
|
61.3 |
69.4 |
80.3 |
89.1 |
106.9 |
116.9 |
134.8 |
155.4 |
Minority interests |
(0.2) |
(0.2) |
(0.1) |
(0.8) |
(0.8) |
(0.9) |
(1.0) |
(1.1) |
||
Shareholders' equity |
|
|
61.1 |
69.2 |
80.2 |
88.3 |
106.1 |
116.0 |
133.8 |
154.3 |
CASH FLOW |
||||||||||
Op Cash Flow before WC and tax |
23.3 |
26.0 |
27.6 |
29.7 |
33.0 |
41.7 |
48.5 |
53.1 |
||
Working capital |
4.2 |
(0.3) |
(4.1) |
(4.6) |
(6.1) |
0.4 |
(10.0) |
(4.1) |
||
Exceptional & other |
0.4 |
(0.5) |
1.9 |
0.6 |
5.1 |
(6.3) |
0.0 |
0.0 |
||
Tax |
(4.3) |
(5.0) |
(3.6) |
(4.7) |
(4.1) |
(6.1) |
(3.9) |
(7.5) |
||
Net operating cash flow |
|
|
23.6 |
20.2 |
21.8 |
21.0 |
27.9 |
29.7 |
34.6 |
41.5 |
Capex |
(4.7) |
(3.2) |
(5.8) |
(5.4) |
(6.8) |
(10.1) |
(15.5) |
(11.2) |
||
Acquisitions/disposals |
(1.6) |
0.1 |
0.1 |
(8.3) |
0.1 |
(18.3) |
(31.8) |
0.0 |
||
Net interest |
(0.5) |
(0.3) |
(0.1) |
(0.1) |
(0.2) |
(0.2) |
(1.2) |
(1.6) |
||
Equity financing |
(0.5) |
0.1 |
(0.2) |
0.0 |
0.2 |
(0.2) |
0.0 |
0.0 |
||
Dividends |
(9.1) |
(10.1) |
(11.0) |
(12.2) |
(13.1) |
(14.2) |
(15.5) |
(16.2) |
||
Other |
0.5 |
0.2 |
0.1 |
0.2 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Net Cash Flow |
7.7 |
7.0 |
4.9 |
(4.8) |
8.1 |
(13.3) |
(29.3) |
12.5 |
||
Opening net debt/(cash) |
|
|
18.6 |
10.6 |
3.5 |
(1.3) |
3.7 |
(3.7) |
9.0 |
38.3 |
FX |
0.3 |
0.1 |
(0.1) |
(0.2) |
(0.5) |
0.7 |
0.0 |
0.0 |
||
Other non-cash movements |
0.0 |
0.0 |
0.0 |
0.1 |
(0.2) |
(0.1) |
0.0 |
0.0 |
||
Closing net debt/(cash) |
|
|
10.6 |
3.5 |
(1.3) |
3.7 |
(3.7) |
9.0 |
38.3 |
25.8 |
Source: <Insert Source or Notes>
Source: XP Power, Edison Investment Research
|
|
Research: Healthcare
Laboratorios Farmacéuticos ROVI’s (ROVI) investment case rests on the growth opportunities in its speciality pharmaceuticals portfolio, in particular the ongoing European roll-out of its biosimilar enoxaparin. However, over the next 12-18 months we expect increased investor interest in the proprietary ISM-patented R&D pipeline. Risperidone ISM or DORIA, a long-acting injectable (LAI) for schizophrenia, is due to read out data in Q219 from the ongoing Phase III PRISMA-3 trial. DORIA’s potential US and EU approval (2020) and launch (2021) will validate ROVI’s long-acting formulation capabilities. With peak sales opportunities of US$411m (US and EU), this high gross margin product will be highly value enhancing to ROVI’s long-term profit growth. We value ROVI at €1.16bn or €23.3/share.